Pharmacology of niacin or nicotinic acid;Farmacologia da niacina ou ácido nicotínico

Arquivos Brasileiros de Cardiologia

Volumn 85, Issue SUPPL. 5, 2005, Pages 17-19

  Santos, Raul D ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Dyslipidemia; Niacin; Nicotinic acid

Indexed keywords

ANTILIPEMIC AGENT; FATTY ACID; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIVER ENZYME; NICOTINIC ACID; TRIACYLGLYCEROL; URIC ACID;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADIPOCYTE; ARTICLE; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CORONARY RISK; DRUG ABSORPTION; DRUG MECHANISM; DRUG TOLERABILITY; DYSPEPSIA; ENZYME BLOOD LEVEL; FATTY ACID TRANSPORT; FLUSHING; GLUCOSE BLOOD LEVEL; HUMAN; LIPID METABOLISM; LIVER TOXICITY; MORTALITY; PHARMACOLOGICAL PARAMETERS; RISK REDUCTION; SIDE EFFECT; SOLUBILITY; SUSTAINED DRUG RELEASE; URIC ACID BLOOD LEVEL;

ANTILIPEMIC AGENTS; DELAYED-ACTION PREPARATIONS; DYSLIPIDEMIAS; FLUSHING; HUMANS; NIACIN;

EID: 31144454453     PISSN: 0066782X     EISSN: 16784170     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Karpe F, Frayn KN. The nicotinic acid receptor - a new mechanism for an old drug. Lancet. 2004; 363:1892-94.
2. Santos RD, Giannini SD, Fonseca FAH et al. III Diretrizes brasileiras sobre dislipidemias e diretriz de prevenção da aterosclerose do departamento de aterosclerose da sociedade brasileira de cardiologia. Arq Bras Cardiol. 2001;77 (supl III):1-48.
3. Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA. 1975;231:360-381.
4. Canner PL, Berge KG, Wenger NK, Stamler J, Friedman L, Prineas RJ, Friedewald W. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986;8:1245-55.
5. Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 1987; 257:3233-40.
6. Brown G, Albers JJ, Fisher LD et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323:1289-98.
7. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345:1583-92.
8. Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation. 2004;110:3512-7
9. Brewer HB Jr. Focus on high-density lipoproteins in reducing cardiovascular risk. Am Heart J. 2004;148(Suppl):S14-8.
10. McKenney J. New perspectives on the use of niacin in the treatment of lipid disorders. Arch Intern Med. 2004;164:697-705.
11. Grundy SM, Vega GL, McGovern E et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes. Arch Intern Med. 2002;162:1568-1576.
12. Shek A, Ferrill MJ. Statin-fibrate combination therapy. Ann Pharmacother. 2001;35:908-17.
13. I Diretriz Brasileira de Diagnóstico e Tratamento da Síndrome Metabólica. Hipertensão. 2004;7:126-159.